ArticleNature immunology2023
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 1 pooled it
19.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 1 synthesis or guideline pooled it, 239 citations in OpenAlex.
- Hypoxia-pyroptosis-associated long noncoding RNAs as prognostic biomarkers in lung cancer: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Nature communications · 2024Trial
- TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.Nature communications · 2024Trial
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- CD39 on CD8European journal of immunology · 2026Review
- Augmenting CAR T cell functionality and metabolism through CD39 downtuning.Molecular therapy. Oncology · 2026Article
- Decoding neuro-tumor interactions in pancreatic cancer: mechanisms, immunosuppressive networks and therapeutic opportunities.Molecular biomedicine · 2026Review
- Impaired regulation by purinergic signaling axis contributes to CD8+ T cell dysregulation in STAT3 gain of function.JCI insight · 2026Article
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Hypoxia during GPC2-CAR T-cell manufacturing compromises cell expansion and cytotoxic capacity.Cytotherapy · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity.Cancer research · 2026Article
- Tumor microenvironment-specific nanomedicine: from biology-driven to multi-omics-guided precision engineering.Journal of hematology & oncology · 2026Review
- Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function.bioRxiv : the preprint server for biology · 2026Article
- The Trifecta of Polo-Like Kinases, Cancer, and the Immune System: Emerging Intersections and Therapeutic Insights.Molecular cancer research : MCR · 2026Review
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Article
- From guardians to traitors: molecular mechanisms of tumor-induced T cell betrayal.Molecular cancer · 2026Review
- Unlocking Wnt's weak spot: Glycosylated nanoalbumins to reignite immune responses in MSS-CRC.Journal of pharmaceutical analysis · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Paolo D A VignaliDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Kristin DePeaux *Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-8460-727X
McLane J Watson *Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Chenxian YeDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-2700-3271
B Rhodes FordDivision of Pediatric Rheumatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.
Konstantinos LontosDivision of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-0216-3818
Nicole K McGaaTumor Microenvironment Center, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA.
Nicole E ScharpingDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-9373-4617
Ashley V MenkTumor Microenvironment Center, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA.
Simon C RobsonCenter for Inflammation Research, Department of Anesthesia, Critical Care & Pain Medicine and Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6374-0194
Amanda C PoholekDivision of Pediatric Rheumatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-5587-8940
Dayana B RivadeneiraDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Greg M DelgoffeDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. gdelgoffe@pitt.edu.ORCID http://orcid.org/0000-0002-2957-8135
University of Pittsburgh · USUPMC Hillman Cancer Center · USBeth Israel Deaconess Medical Center · USUniversity of Pittsburgh Medical Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6MTherapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9MTRAINING PROGRAM FOR MD/PHD STUDENTST32GM008208 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEINMAN, RICHARD A · 1987 to 2021
$15.4MTraining in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2MUncovering the metabolic underpinnings of T cell exhaustionR01AI166598 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2022 to 2025
$3.2MDissecting the role of hypoxia in T cell differentiation in cancerR01CA277473 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe, Yana Najjar · 2023 to 2026
$2.4MMetabolic control of regulatory T cell functional identityR01AI171483 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2022 to 2025
$2.4MExploring and exploiting metabolic plasticity in regulatory T cellsDP2AI136598 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2017 to 2017
$2.3MTumor-infiltrating T cell metabolic dysfunction and genetic reprogramming for effective immunotherapyK00CA222711 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHARPING, NICOLE E · 2020 to 2023
$360kTumor-infiltrating terminally exhausted CD8+ T cells augment the suppressive microenvironment within solid tumorF30CA247034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, PAOLO DARIO ANGELO · 2020 to 2023
$209kCauses and consequences of oncolytic virus infection of non-tumoral cells in cancer immunotherapyF31CA247129 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEPEAUX, KRISTIN LEIGH · 2020 to 2021
$92kNCI NIH HHS F30 CA247034NCI NIH HHS F31 CA247129NCI NIH HHS F99 CA222711NCI NIH HHS K00 CA222711NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA277473NCI NIH HHS T32 CA082084NIAID NIH HHS DP2 AI136598NIAID NIH HHS F31 AI149971NIAID NIH HHS R01 AI166598NIAID NIH HHS R01 AI171483NIGMS NIH HHS T32 GM008208
Abstract
CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAntigens, CDApyraseHumansHypoxiaT-Lymphocytes, RegulatoryTumor MicroenvironmentAntigens, CDApyraseCD39 antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.